Treatment of congenital Langerhans cell histiocytosis with cobimetinib.
Pediatr Dermatol
; 41(3): 515-517, 2024.
Article
em En
| MEDLINE
| ID: mdl-38387093
ABSTRACT
We report a case of congenital multisystem Langerhans cell histiocytosis with cutaneous and hematopoietic involvement. After the failure of first-line (vinblastine and prednisolone) and second-line (vincristine and cytarabine) therapies, treatment with cobimetinib, a mitogen-activated protein kinase (MEK) inhibitor, led to the remission of disease and a sustained response after 11 months of ongoing treatment. Protein kinase inhibitors targeting BRAF or MEK could represent a promising future therapeutic option, also in children with LCH.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Piperidinas
/
Azetidinas
/
Histiocitose de Células de Langerhans
Limite:
Female
/
Humans
/
Infant
/
Male
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article